Sirnaomics Announces 2023 Annual Results
Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/...
Stay updated with breaking news from Patrick Lu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/...
Focuses on the Consolidation for Leading Projects
Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging ...
By Karen E. Roman Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors. The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle formulation, and provided a foundation for further research to treat hepatocellular carcinoma and other solid tumors, […]
GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today...